Expression of 5α-Reductase Type 2 Gene in Human Testis, Epididymis and Vas Deferens

Objectives To study the expression pattern of 5α-reductase type 2 gene in human male reproductive organsMethods The expression level of 5α-reductase type 2 gene inhuman testis, epididymis and vas deferens tissues was determined by in situ hybridization using Digoxin labeled 5α-reductase type 2 cRNA probe.Results The brown granules of hybridizing signals distributed in the cytoplasm of Sertoli and Leydig cells of the testis, the principle cells of epididymis and the epithelial cells of vas deferens, but there was no positive signal in the nuclei of above-mentioned cells. No positive signal was observed in germ cells, basement of the testis, interstium of epididymis and basement, as well as smooth muscle of vas deferens. Conclusion This study confirmed that the 5α-reductase type 2 gene expressed in Sertoli , Leydig cells of the testis, and the principle cells of epididymis. The expression pattern of the gene in these cells in human was similar to that of rat and monkey. The presence of 5α-reductase t     

医源性腓总神经伤分析

目的：总结40a来收治的48例医源性腓总神经损伤的临床资料，探讨其损伤机制和特点。方法：通过随访，依据其损伤原因和机制分类统计。结果：牵拉压迫伤33例，占69％；手术切割伤12例，占25％。导致腓总神经损伤的原因中以石膏压迫为最多，占37％，牵伸性损伤占31％。结论：骨科医师必须具备丰富的解剖知识和责任心，重在预防，一旦发生损伤，应早期诊断，采用有效的方法及时治疗。     

巨噬细胞炎性蛋白4的突变和原核表达

目的 探索如何抑制嗜酸细胞的趋化作用，选择β-趋化因子巨噬细胞炎性蛋白4（MIP4）的突变性（Met-MIP4)作为趋化因子受体3的拮抗剂，将Met-MIP4基因在原核细胞中进行表达。方法 设计MIP4基因的PCR引物并进行氨基酸突变，将MIP4N末端的丙氨酸突变为蛋氨酸，以正常人肺酸突变，将MIP4N末端的丙氨酸突变为蛋氨酸。以正常人肺cDNA文库为模板，PCR方法获取Met-MIP4基因，克隆入载体pUC19，测序验证序列已得到突变，将正确的基因插入到GST融合表达载体pGEX-4T中，以IPTG诱导表达。结果 PCR产物为220bp左右的片段，连接入pUC19质粒后测序验证获得正确突变，构建的pGEX-4T融合表达载体在大肠杆菌中表达，经SDS-PAGE凝胶电泳显示有大小约34kU的新生融合蛋白表达。结论 成功突变并克隆了β-趋化因子MIP4基因，SDS-PAGE表明，与GST融合的Met-MIP4突变体已得到表达，为进一步研究其生物学活性奠定了基础。     

肠腔侧侧分流术治疗门静脉高压症的体会

本文报道了肠系膜上静脉与下腔静脉侧侧分流术7例,并介绍了手术的体会,认为应解剖、暴露肠系膜上静脉“外科干”与相应平面的下腔静脉,清除两者间的增生组织,缩短两者的间距,才易取得手术成功。本术既可使门静脉压下降适中,又对门静脉向肝血流干扰较小,且对组织损伤较轻。     

Use of a synthetic peptide-based elisa for the diagnosis of infectious mononucleosis and other diseases

A simple enzyme immunoassay has been developed based on measuring antibodies to synthetic peptides corresponding to sequences in the Epstein-Barr nuclear antigen (EBNA). This assay, which is reproducible, quantitative, and simple to perform and interpret, can be an effective tool to aid in the diagnosis of infectious mononucleosis and nasopharyngeal carcinoma.     

HO-1、HO-1 mRNA在肝硬化病人肝组织中的表达及与门静脉压力的关系

目的　观察HO CO系统在肝硬化病人肝组织中的表达及与门静脉压力的关系 ,以探讨其在肝硬化门脉高压中的作用。方法　随机选取 2 0例正常志愿者及 2 0例肝硬化患者 ,在B超引导下经皮经肝穿刺分别测定门静脉压力、抽取门静脉血和外周血并留取肝组织 ,测定血液中CO浓度 ,用免疫组化和RT PCR方法观察肝组织HO 1及其HO 1mRNA的表达。结果　肝硬化病人下腔静脉及门静脉血中CO浓度、肝组织HO 1、HO 1mRNA的表达及门静脉压力均分别显著高于正常对照组 ,正常对照组的外周血和门静脉血中CO浓度水平接近 ,无明显差异 ;但肝硬化患者的门静脉血CO浓度显著高于外周血CO浓度。结论　门脉血CO浓度、肝组织中HO 1以及HO 1mRNA表达与门静脉压力密切相关     

人脑胶质瘤中cyclinD1/bcl-1和p27/kip1的表达与病理、预后的相关性研究

目的 :研究cyclinD1 bcl 1和p2 7 kip1在脑胶质瘤中表达及其与病理分级和患者预后的关系。方法 :用免疫法组化技术对 4 8例不同恶性程度 (WHO分类法 )的脑胶质瘤组织和 12例非肿瘤组织中cyclinD1 bc1 1和p2 7 kip1蛋白的表达作了检测 ,用图像分析系统定量分析 ,并与临床资料紧密相联系进行统计学处理。结果 :两种蛋白的免疫反应复合物定位于细胞核。其在脑胶质瘤中的阳性表达都高于非肿瘤组织 (P <0 0 5 ) ,cyclinD1 bcl 1阳性颜色的数量和强度都随肿瘤的恶性程度升高而增加 (P <0 0 5 ) ,相反p2 7 kip1阳性染色的数量和强度都随肿瘤的恶性程度升高而降低 (P <0 0 5 )。cyclinD1 bcl 1的高表达或 和p2 7 kip1的低表达预示着预后差。结论 :CyclinD1 bcl 1和p2 7 kip1的异常表达可能与脑胶质瘤的发生发展密切相关 ,二者可能有协同作用。二者的表达都可作为判断预后的一个指标     

局灶性脑缺血对细胞周期蛋白D1/CDK4基因表达的影响

目的观察脑缺血后细胞周期蛋白（cyclin）D1和它的酶CDK4基因表达，以及这种表达的改变是否影响神经细胞凋亡。方法成年雄性SD大鼠32只随机分为假手术组（n=4）和实验组（n=28），实验组再进一步分为7个亚组（再灌注2h，6h，12h，1d，3d，7d和14d，每组n=4）。应用线栓法建立SD大鼠大脑中动脉阻塞／再灌注模型．TUNEL法检测神经细胞凋亡。原位杂交检测cyclinD1和CDK4mRNA的表达。结果CyclinD1mRNA和CDK4mRNA的表达与凋亡细胞的区域基本相同。再灌注2h脑组织即开始出现神经细胞凋亡，并于1d分别在皮层区和纹状体区达高峰（分别为72．80±4．66和87．75±0．85）。神经细胞cyclinD1mRNA和CDK4mRNA的表达分别于再灌注2h和6h开始逐渐增强，并于12h和1d达高峰（皮质区分别为94．50±2．75和85．75±3．73，纹状体区分别为88．25±5．06和89．80±2．93）。结论CyclinD1和CDK4选择性地在形态学完整或已经有改变的缺血侧神经元和少突胶质细胞内表达。CyclinD1／CD1（4mRNA表达可能是诱导细胞凋亡的重要因素之一。     

Pilot study to enhance HIV care using needle exchange-based health services for out-of-treatment injecting drug users

The introduction of highly active antiretroviral therapy (HAART) has resulted in marked reductions in mortality and acquired immunodeficiency syndrome (AIDS) incidence across all risk groups; however, the proportionate decrease among injecting drug users (IDUs) has been less impressive. Much of the disparity in benefit to IDUs has been a consequence of decreased access to and receipt of potent antiretroviral combinations. Strategies to increase access to and utilization of HAART have included entry into drug treatment and abstinence. Unfortunately, as few as 15%–20% of active drug users in the United States, and in many other countries, are in drug treatment at any one time. We report a pilot project among out-of-drug treatment IDUs infected with human immunodeficiency virus (HIV); HIV therapy was successfully provided to active heroin injectors using the Community Health Care Van (CHCV) at sites of needle exchange. Subjects were willing to initiate, but were not receiving, recommended HIV therapy and were not interested in formal drug treatment. Antiretroviral therapy regimens were selected and linked to heroin injection timing. Weekly visits were scheduled by CHCV staff to assess adverse side effects and encourage adherence. Of the 13 participants, the mean baseline HIV-1 RNA level and CD4 lymphocyte count were 162,369 (log 5.21) copies per milliliter and 265 cells per milliliter, respectively. By 6 months, the proportion whose HIV-1 RNA was below the limits of detection (<400 copies/mL) was 85% (N=11); 77% (N=10) had nondetectable levels by 9 months. By 12 months, 54% (N=7) had a persistently nondetectable viral load, and the net increase in CD4 lymphocyte count was 150 cells per milliliter. As an additional and unintended benefit of this pilot project, 9 (69%) subjects chose to enter drug treatment after achieving a nondetectable viral load. Entry into drug treatment was associated with durability of viral suppression. This small pilot study suggests that health services based on needle exchange may enhance access to HAART among out-of-treatment HIV-infected IDUs. In addition, it demonstrates that this population can benefit from this therapy with the support of a nontraditional, community-based health intervention.     

人T淋巴母细胞（Jurkat）移动性的研究

利用人Ｔ淋巴母细胞（Ｊｕｒｋａｔ）细胞系作为研究对象。企图探探索细胞外基质成份及肌醇磷脂细胞信息传递系统与细胞移动的关系。研究结果表明：当细胞被伏波醇酯（ＰＭＡ）处理过后，其粘连性与移动件对纤维连结蛋白（ＦＮ）底物的反应在已是高水平的基础上有更进一步提高的作用。与ＦＮ刊相反的是，未经ＰＭＡ处理处的Ｊｕｒｋａｔ细胞对层粘连蛋白（Ｌｍ）底物却无明显的粘连性及移动性增加的反应，尽管在ＰＭＡ处理过４小时内亦无任何的增强。但是，当ＰＭＡ作用于细胞２４一４８小时后则明显池增加其Ｌｍ底物的粘连性及移动性反应，表明了其明显的协同作用。分别用抗ＦＮ、抗Ｌｍ及蛋白激酶Ｃ抑制剂Ｓｔａｕｒｏｓｐｒｉｎｅ（ＳＰ）时均起到特异性的抑制作用。可见，协同作用的产生是通过蛋白激酶Ｃ激活后的－段时间内，使细胞表面Ｌｍ受体密度增加而对底物Ｌｍ反应增强所致。